Comparing WuXi PharmaTech (Cayman) (WX) and Sunesis Pharmaceuticals (NASDAQ:SNSS)

WuXi PharmaTech (Cayman) (NYSE: WX) and Sunesis Pharmaceuticals (NASDAQ:SNSS) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Institutional and Insider Ownership

39.5% of Sunesis Pharmaceuticals shares are owned by institutional investors. 10.2% of Sunesis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares WuXi PharmaTech (Cayman) and Sunesis Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
WuXi PharmaTech (Cayman) N/A N/A N/A $1.18 38.91
Sunesis Pharmaceuticals $2.54 million 74.84 -$38.02 million ($1.75) -3.17

WuXi PharmaTech (Cayman) has higher earnings, but lower revenue than Sunesis Pharmaceuticals. Sunesis Pharmaceuticals is trading at a lower price-to-earnings ratio than WuXi PharmaTech (Cayman), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares WuXi PharmaTech (Cayman) and Sunesis Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
WuXi PharmaTech (Cayman) 7.52% 6.93% 4.67%
Sunesis Pharmaceuticals N/A N/A -125.56%

Analyst Recommendations

This is a summary of recent recommendations for WuXi PharmaTech (Cayman) and Sunesis Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WuXi PharmaTech (Cayman) 0 0 0 0 N/A
Sunesis Pharmaceuticals 0 2 2 0 2.50

Sunesis Pharmaceuticals has a consensus price target of $4.16, indicating a potential downside of 25.05%. Given Sunesis Pharmaceuticals’ higher possible upside, analysts plainly believe Sunesis Pharmaceuticals is more favorable than WuXi PharmaTech (Cayman).

About WuXi PharmaTech (Cayman)

WuXi PharmaTech (Cayman) Inc. is a pharmaceutical, biotechnology and medical device research and development (R&D) services company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers. It conducts its operations in two segments: Laboratory services and Manufacturing services. The Company offers Laboratory services for pharmaceutical, biotechnology and medical device companies. It offers Manufacturing services, which include the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients (APIs) for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologic products.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

Receive News & Ratings for WuXi PharmaTech (Cayman) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi PharmaTech (Cayman) and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply